Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4529751 | 0.79 | MAP4K4 (0.44) | MAP4K4SMN1; SMN2 | |
| SCHEMBL823714 | 0.79 | MAPT (0.40) | DYRK1AMAP4K4SMN1; SMN2 | |
| Morpholine SCHEMBL4524928 | 0.78 | PDE5A (0.35) | MAP4K4 | |
| SCHEMBL3599474 | 0.78 | ADORA2A (0.49) | MAP4K4 | |
| SCHEMBL4513221 | 0.78 | RXFP1 (0.43) | MAP4K4SMN1; SMN2 | |
| SCHEMBL4533861 | 0.77 | PIK3CG (0.43) | DYRK1AMAP4K4 | |
| SCHEMBL4122428 | 0.77 | MPO (0.39) | TLR7TLR8MAP4K4 | |
| SCHEMBL4525197 | 0.76 | ALDH1A1 (0.52) | TLR8MAP4K4SMN1; SMN2 | |
| SCHEMBL4534215 | 0.76 | ALDH1A1 (0.47) | DYRK1APARP1HRH3SMN1; SMN2 | |
| SCHEMBL4526926 | 0.75 | ALDH1A1 (0.43) | DYRK1AMAP4K4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | TLR7 851/4885TLR8 1791/4885JAK2 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.